;)
Matica Open Access Platform empowers clients to leverage Matica Bio’s technologies and capabilities without platform lock-in, enabling development strategies aligned to each client’s unique goals.
In contrast to traditional CDMOs that require adoption of predefined platforms or locked-down tech-transfer models, Matica Bio operates through a single, flexible open-access framework. This approach delivers faster timelines, clearer visibility, and greater client control, whether starting from early development or an established process.
How Does It Work
What Makes Open Access Platform Different
- No fixed platforms, mandatory adoptions of predefined platform or restrictive tech-transfer packages
- Single open-access framework that supports flexible engagement at any stage
- Clients retain control over process design and decision-making – NOT CDMO
How Clients Gain From Open Access Platform
- Accelerated and predictable timelines with faster execution
- Greater control, transparency and program visibility
- Freedom to start from early development or an existing process
Why It Matters
- Reduced development risk without sacrificing flexibility
- Easier adaptation as programs evolve to future proof programs
- Stronger alignment with sponsor, investor, and regulatory expectations
Scope of Work
- Proof of Concept Runs in Process Development (1 x 10L AAV)
- Analytical Development (Genomic Copies, Particle Titer (LVV), Capsid ELISA (AAV), Residual Plasmid)
- Analytical Verification (Host Cell DNA, Host Cell Protein)
- Program Management and Technical Support (Oversight, Guidance, and Client Excellence satisfaction)
Advantages of Open Access Platform
| ADVANTAGES | TRADITIONAL PLATFORM | MATICA OPEN ACCESS PLATFORM |
|---|---|---|
| Access to Infrastructure, Process, and Resources | ✓ | ✓ |
| Accelerated Timeline Through Standardized Process (3-4 Months) | ✓ | ✓ |
| Open Access to developed Assays, Process and Data | ✓ | |
| Affordable and Predictable Cost with Confidence (No Develop. Change Order Fees) | ✓ | |
| NO Platform Access Fees / No Cell Line Milestone & Royalty Fees | ✓ | |
| Asset Transferability and Exit Strategy for Sponsors | ✓ | |
| Increased Attractiveness for investment and Pharma Partners | ✓ | |
| Overall Greater Control – Your Science. Your Way. | ✓ |